| Literature DB >> 34368036 |
Jingfeng Chen1, Zhuoqing Wu2, Yanan Liu1, Lin Wang1, Tiantian Li1, Yihan Dong1, Qian Qin1, Suying Ding1.
Abstract
Objective: The critical values in health checkup play a key role in preventing chronic diseases and different types of cancer. This study aimed to analyze the prevalence, association relation, and dynamic evolution of critical values in health checkups at a large physical examination center in China.Entities:
Keywords: association relation analysis; critical values in health checkup; dynamic evolution analysis; health managament; prevalence analysis
Year: 2021 PMID: 34368036 PMCID: PMC8339420 DOI: 10.3389/fpubh.2021.630356
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1Study design and flow diagram.
The critical value list in health checkup for a laboratory test.
| Routine Blood Test (Blood_T) | WBC count | ≤ 2 × 109/L, ≥20 × 109/L |
| Platelet count | ≤ 30 × 109/L, ≥1000 × 109/L | |
| Hemoglobin | ≤ 60 g/L | |
| Blood Glucose Test (Glucose_T) | Glucose | ≥16.7 mmol/L and ≥13.9 mmol/L with strong positive urine ketone body |
| Glycosylated hemoglobin | ≥15% | |
| Liver Function Test (Liver_T) | Alanine aminotransferase | ≥100 U/L |
| Aspartate aminotransferase | ≥100 U/L | |
| Glutamyl transpeptidase | ≥200 U/L | |
| Total bilirubin | ≥85.5 μmol/L | |
| Kidney Function Test (Kindney_T) | Creatinine | >115 μmol/L |
| Blood Lipid Test (Lipid_T) | Triglyceride | ≥15 mmol/L |
| Thyroid Function Test (Thyroid_T) | Free triiodothyronine | ≥2 × maximum reference value |
| Free thyroxine | ||
| Thyroid stimulating hormone | ||
| Routine Urine Test (Urine_T) | Occult blood | ≥3 + |
| Pathological cast | ≥1/μL | |
| Transparent tube type | ≥2/μL | |
| Ketone body | ≥2 + | |
| Glucose | ≥4 + | |
| Protein | ≥3 + | |
| Tumor Marker Test (Tumor_T) | Alpha fetoprotein, Carcinoembryonic antigen | ≥2 × maximum reference value |
| Ca72-4, Ferritin | ≥3 × maximum reference value | |
| Ca125, Ca19-9 | ≥maximum reference value | |
| Tumor abnormal protein | ≥160 μm2 | |
| Total prostate specific antigen | ≥4 ng/ml |
The critical value list in health checkup informed on site.
| Measurement of height and weight(Obesity) | Body mass index (BMI) = weight/(height)2: BMI≥30(Kg/m2) |
| Blood pressure measurement(Hypertension) | Systolic blood pressure (SBP)≥180(mmHg) or Diastolic blood pressure (DBP)≥110(mmHg) |
The prevalence and significance analysis of critical values in health checkup.
| Obesity | 2154 (6.40%) | 1762 (9.18%) | 392 (2.71%) | 576.17 | |
| Hypertension | 519 (1.54%) | 373 (1.94%) | 146 (1.01%) | 47.35 | |
| Blood_T | 75 (0.22%) | 18 (0.09%) | 57 (0.39%) | 33.47 | |
| Glucose_T | 86 (0.26%) | 65 (0.34%) | 21 (0.15%) | 12.11 | |
| Liver_T | 248 (0.74%) | 196 (1.02%) | 52 (0.36%) | 49.35 | |
| Kindney_T | 81 (0.24%) | 68 (0.35%) | 13 (0.09%) | 24.01 | |
| Lipid_T | 18 (0.05%) | 15 (0.08%) | 3 (0.02%) | 5.08 | |
| Thyroid_T | 20 (0.06%) | 9 (0.05%) | 11 (0.08%) | 1.18 | 0.277 |
| Urine_T | 205 (0.61%) | 174 (0.91%) | 31 (0.21%) | 65.26 | |
| Tumor_T | 274 (0.81%) | 146 (0.76%) | 128 (0.89%) | 1.58 | 0.208 |
| Thyroid_US | 570 (1.69%) | 240 (1.25%) | 330 (2.28%) | 52.72 | |
| Cardiac_US&CT | 31 (0.09%) | 23 (0.12%) | 8 (0.06%) | 3.73 | 0.053 |
| Abdominal_US | 117 (0.35%) | 70 (0.36%) | 47 (0.33%) | 0.38 | 0.54 |
| Neck_US | 44 (0.13%) | 30 (0.16%) | 14 (0.1%) | 2.24 | 0.135 |
| Urinary_US | 71 (0.21%) | 39 (0.2%) | 32 (0.22%) | 0.13 | 0.72 |
| Pelvic_US | 46 (0.3%) | 2 (0.01%) | 44 (0.3%) | ||
| Breast_US&MG | 93 (0.64%) | 93 (0.64%) | |||
| TCT&HPV | 97 (0.67%) | 97 (0.67%) | |||
| ECG | 321 (0.95%) | 189 (0.99%) | 132 (0.91%) | 0.45 | 0.502 |
| Lung_CT&X | 278 (0.83%) | 168 (0.88%) | 110 (0.76%) | 1.32 | 0.25 |
| Head_CT | 109 (0.32%) | 73 (0.38%) | 36 (0.25%) | 4.41 | |
| All | 4721 (14.03%) | 3141 (16.37%) | 1580 (10.93%) | 206.16 |
Denotes a statistically significant difference (P < 0.05).
Denotes a statistically significant difference (P < 0.01).
Only for the female.
Figure 2The prevalence of critical values in health checkup for different genders. * and ** denote the statistically significant difference in the 0.05 and 0.01 tested levels.
The significance analysis of critical values for different ages and genders.
| 18–30 | Male (1,090) | 106 | 2 | 8 | 11 | 6 | 5 | 153 (14.04%) |
| Female (951) | 12 | 1 | 17 | 15 | 8 | 8 | 58 (6.10%) | |
| 66.53 | 4.66 | 1.27 | 0.63 | 1.17 | 34.52 | |||
| 0.25 | 0.43 | 0.279 | ||||||
| 31–40 | Male (5,676) | 640 | 58 | 53 | 38 | 28 | 23 | 894 (15.75%) |
| Female (4,673) | 103 | 9 | 93 | 43 | 28 | 27 | 380 (8.13%) | |
| 316.49 | 27.40 | 20.56 | 2.07 | 0.53 | 1.59 | 137.81 | ||
| 0.15 | 0.47 | 0.21 | ||||||
| 41–50 | Male (5,331) | 505 | 126 | 63 | 45 | 41 | 43 | 847 (15.89%) |
| Female (3,811) | 82 | 23 | 93 | 43 | 28 | 27 | 410 (10.76%) | |
| 198.24 | 42.94 | 20.99 | 1.88 | 0.04 | 0.28 | 149.31 | ||
| 0.17 | 0.85 | 0.6 | ||||||
| 51–60 | Male (4,432) | 327 | 81 | 72 | 32 | 59 | 46 | 716 (16.16%) |
| Female (2,945) | 76 | 26 | 85 | 14 | 26 | 18 | 330 (11.21%) | |
| 78.85 | 11.05 | 13.52 | 1.74 | 3.12 | 3.75 | 35.62 | ||
| 0.19 | 0.08 | 0.05 | ||||||
| 61–70 | Male (1,681) | 116 | 59 | 24 | 14 | 25 | 26 | 296 (17.61%) |
| Female (1397) | 66 | 29 | 46 | 8 | 18 | 24 | 225 (16.11%) | |
| 6.50 | 5.65 | 11.94 | 0.73 | 0.22 | 0.14 | 1.23 | ||
| 0.39 | 0.64 | 0.71 | 0.268 | |||||
| >70 | Male (969) | 68 | 47 | 20 | 6 | 30 | 25 | 235 (24.25%) |
| Female (668) | 53 | 58 | 14 | 0 | 23 | 16 | 177 (26.50%) | |
| 0.485 | 9.67 | 0 | 0.15 | 0.06 | 1.06 | |||
| 0.486 | 0.97 | 0.70 | 0.81 | 0.304 | ||||
Denotes a statistically significant difference (P < 0.05).
Denotes a statistically significant difference (P < 0.01).
Figure 3The prevalence trend of critical values along with age for the male and female. **Denotes a statistically significant difference (P < 0.01).
The detailed results of the identified effective and strong rules.
| Male | 1 | {Glucose_T,Tumor_T} ≥ {Urine_T} | 0.01 | 1 | 4.44 | 6 |
| 2 | {Glucose_T,Hypertension} ≥ {Urine_T} | 0.01 | 1 | 4.44 | 5 | |
| 3 | {Liver_T,Urine_T} ≥ {Glucose_T} | 0.02 | 0.88 | 5.82 | 7 | |
| 4 | {Tumor_T,Urine_T} ≥ {Glucose_T} | 0.01 | 0.86 | 5.71 | 6 | |
| 5 | {Glucose_T} ≥ {Urine_T} | 0.13 | 0.84 | 3.74 | 54 | |
| 6 | {Glucose_T,Liver_T} ≥ {Urine_T} | 0.02 | 0.78 | 3.45 | 7 | |
| 7 | {Hypertension} ≥ {Obesity} | 0.19 | 0.71 | 1.34 | 83 | |
| 8 | {Glucose_T,Thyroid_US} ≥ {Urine_T} | 0.01 | 0.63 | 2.77 | 5 | |
| 9 | {Liver_T} ≥ {Obesity} | 0.08 | 0.56 | 1.07 | 36 | |
| 10 | {Urine_T} ≥ {Glucose_T} | 0.13 | 0.56 | 3.74 | 54 | |
| 11 | {Thyroid_US,Urine_T} ≥ {Glucose_T} | 0.01 | 0.56 | 3.7 | 5 | |
| 12 | {Glucose_T,Obesity} ≥ {Urine_T} | 0.01 | 0.56 | 2.47 | 5 | |
| 13 | {Hypertension,Urine_T} ≥ {Glucose_T} | 0.01 | 0.5 | 3.33 | 5 | |
| 14 | {Thyroid_US} ≥ {Obesity} | 0.06 | 0.44 | 0.82 | 27 | |
| 15 | {Abdominal_US} ≥ {Lung_CT&X} | 0.04 | 0.43 | 3.23 | 17 | |
| 16 | {Cardiac_US&CT} ≥ {ECG} | 0.01 | 0.42 | 3.35 | 5 | |
| Female | 1 | {Urine_T} ≥ {Glucose_T} | 0.07 | 0.75 | 7.58 | 15 |
| 2 | {Glucose_T} ≥ {Urine_T} | 0.07 | 0.75 | 7.58 | 15 | |
| 3 | {Hypertension} ≥ {Obesity} | 0.13 | 0.6 | 1.92 | 27 | |
| 4 | {Neck_US} ≥ {Thyroid_US} | 0.01 | 0.43 | 1.31 | 3 | |
| 5 | {Obesity} ≥ {Hypertension} | 0.13 | 0.43 | 1.92 | 27 | |
| 6 | {Urinary_US} ≥ {Thyroid_US} | 0.02 | 0.42 | 1.28 | 5 |
Figure 4(A,B) The effective association rules for the male and the female participants. A rule was composed of boxes, arrows, and a circle; the blue and red arrows were the critical values on LHS and RHS; and the size and the color of the circle showed the support of the critical value on LHS and the lift of the rule, respectively.
Figure 5The incidence of emerging and persistent critical values for the participants with follow-up physical examination. †Denotes no critical value in the previous year but new critical values in the next year, ‡denotes critical values in the previous year and new critical values in the next year, and ♀denotes critical values in the previous year and the next year. *Denotes a statistically significant difference (P < 0.05), **denotes a statistically significant difference (P < 0.01).
Figure 6The effective evolution paths for men and women. 2017 → 2018 and 2018 → 2019 denote the same participants with at least one critical value in 2017 and 2018 and 2018 and 2019, respectively. The critical values were shown when the transition probability exceeded 0.2.
The incidence and the mortality of malignant tumors and NCDs with partial critical values.
| Lung | 57.26 | 73.9 | 39.78 | 45.87 | 61.52 | 29.43 | Lung_CT&X | 830 | 880 | 760 |
| Stomach | 29.31 | 39.95 | 18.15 | 21.16 | 28.59 | 13.37 | ||||
| Colorectum | 28.2 | 31.96 | 24.25 | 13.61 | 15.56 | 11.58 | ||||
| Liver | 26.92 | 38.98 | 14.26 | 23.72 | 34.31 | 12.6 | Liver_T; Abdominal_US | 740; 350 | 1,020; 360 | 360; 330 |
| Breast | 45.29 | 45.29 | 10.5 | 10.5 | Breast_US&MG | 640 | 640 | |||
| Esophagus | 17.87 | 25.13 | 10.25 | 13.68 | 19.45 | 7.62 | ||||
| Thyroid | 14.6 | 22.56 | Thyroid_T; Thyroid_US | 60; 1,690 | 50; 1,250 | 80; 2,280 | ||||
| Cervix | 16.56 | 16.56 | 5.04 | TCT&HPV; Pelvic_US | 670; 300 | 670; 300 | ||||
| Brain,CNS | 7.72 | 7.04 | 8.43 | 4.1 | 3.1 | 3.77 | Head_CT | 320 | 380 | 250 |
| Pancreas | 6.92 | 7.67 | 6.16 | 4.8 | 5.41 | Abdominal_US | 350 | 360 | 330 | |
| Prostate | 10.23 | 4.36 | Urinary_US | 210 | 200 | 220 | ||||
| Bladder | 8.83 | Urinary_US | 210 | 200 | 220 | |||||
| Lymphoma | 7.43 | 3.62 | 4.38 | Lung_CT&X | 830 | 880 | 760 | |||
| Uterus | 10.28 | Pelvic_US | 300 | 10 | 300 | |||||
| Leukemia | 3.96 | 3.2 | Blood_T | 220 | 90 | 390 | ||||
| Ovary | 3.73 | |||||||||
| Total | 285.83 | 305.47 | 265.21 | 170.05 | 210.1 | 128 | Tumor_T | 810 | 760 | 890 |
| Hypertension and cardiovascular disease | 25,200 | 26,200 | 24,100 | 271.8 | 296.4 | 264.4 | Hypertension; Cardiac_US&CT; Head_CT | 1,540; 90; 320 | 1,940; 120; 380 | 1,010; 60; 250 |
| Diabetes | 11,200 | Glucose_T; Urine_T; Kindney_T | 260; 610; 240 | 340; 910; 350 | 150; 210; 90 | |||||
| Dyslipidemia | 40,400 | 47,000 | 33,500 | Lipid_T | 50 | 80 | 20 | |||
| Total | 23,000 | 533 | 611.2 | 452.6 | Total | 14,030 | 13,770 | 10,930 | ||
Only for the female;
aged 18 and above in China;
aged 40 and above in China;
the total of critical values in health checkup.
The critical value list in health checkup for imaging.
| Thyroid Ultrasound (Thyroid_US) | TI-RADS ≥ category 4; Parathyroid adenoma; Cervical lymph nodes enlargement; Considering lymph node metastasis. |
| Cardiac Ultrasound and Computed Tomography (Cardiac_US&CT) | Ventricular aneurysm; Severe reflux; Ascending aorta widening (widening > 45 mm); Pericardial effusion (large amount); Moderate-severe stenosis (moderate-severe incomplete closure); Aortic aneurysm; Coronary artery stenosis degree > 75%. |
| Abdominal Ultrasound (Abdominal_US) | Liver cirrhosis; Ascites; Severe fatty liver; Liver cyst; Solid space occupying lesions (retroperitoneal space occupying lesions); Solid nodules (further examination); Intrarenal hyperechogenicity (further examination); Intrahepatic and extrahepatic bile ducts Widening (or high limit); Pancreatic lesions (any lesions); Separation of collecting system; Massive pleural effusion; Intrahepatic low-density shadow. |
| Neck Vascular Ultrasound (Neck_US) | Carotid artery stenosis > 50; Moderate-severe stenosis; Internal carotid artery occlusion; Left cervical lymph node enlargement. |
| Urinary System Ultrasound (Urinary_US) | Hydronephrosis (moderate-severe); Small renal volume; Localized thickening of bladder wall; Ureteral dilatation; Separation of renal collecting system; Prostate. |
| Pelvic Ultrasound (Pelvic_US) | Ectopic pregnancy. |
| Breast Ultrasound and Mammography (Breast_US&MG) | BI-RADS category 0 and ≥ category 4A; Space occupying; Shadow. |
| Lung Computed Tomography and Chest X-Ray (Lung_CT&X) | Space occupying; Mediastinum widened; Hilar widened (slightly larger plus data); Pleural effusion (medium and large amount); Suspicious small nodules; Abnormal density shadow; Ground glass nodules. |
| Head Computed Tomography (Head_CT) | High pathological changes >80%; Cerebral vascular stenosis; Cerebral hemorrhage; Aneurysms; Subacute cerebral infarction; Arachnoid cyst; Cerebral hemorrhage; New cerebral infarction; Brain abscess and other signs of canceration. |
The critical value list in health checkup for cervical cancer screening and electrocardiogram.
| Thinprep Cytologic Test and Human Papilloma Virus (TCT&HPV) | TCT: Non benign/reactive lesions; Malignant cells; Low-grade and high-grade intraepithelial lesions; Atypical squamous cells; HPV-16/18 positive. |
| Electrocardiogram(ECG) | Ventricular premature beats (biphasic, triplet, quadruple, multifocal, frequent, ventricular tachycardia, arrest); Atrioventricular block, ventricular arrest and occasional sinus arrest were more than type 2; High potassium, low potassium, low blood calcium, visible atrial escape rate; High and sharpT wave, ST segment elevation (arch back upward) or significantly depressed with T wave inversion; Sinus bradycardia <45, accompanied by long interval of 3S, QT prolongation; Acute myocardial infarction/Brugada wave. |